Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12375261 | 0.97 | MEN1 (0.30) | APEX1 | |
| Hydrochloric Acid SCHEMBL3241042 | 0.86 | APEX1 (0.42) | APEX1NPSR1 | |
| Hydrochloric Acid SCHEMBL3244663 | 0.83 | APEX1 (0.36) | APEX1NPSR1 | |
| Hydrochloric Acid SCHEMBL3242382 | 0.83 | — | — | |
| SCHEMBL12852716 | 0.83 | MEN1 (0.39) | APEX1NPSR1 | |
| SCHEMBL12852652 | 0.81 | — | — | |
| SCHEMBL12852745 | 0.81 | MEN1 (0.33) | APEX1NPSR1 | |
| Hydrochloric Acid SCHEMBL3246950 | 0.79 | DNM1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL2775037 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL3246974 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341886-B1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | claimed |
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| EP-2531026-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | claimed |
| US-8278482-B2 | Antimicrobial N-chlorinated compositions | NOVABAY PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | claimed |
| WO-2011097324-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | claimed |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | NOVABAY PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | claimed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | claimed |
| EP-2265267-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NovaBay Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| US-20100158818-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| WO-2009126912-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| EP-2265267-B1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | GOTTARDI WALDEMAR (AT) | 2016-09-21 | — | — | EP | disclosed |
| EP-2341886-B1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | disclosed |
| EP-2531026-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100158818-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| WO-2009126912-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | APEX1 1332/4885NPSR1 1676/4885CYP3A4 1952/4885 |
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | APEX1 2504/4885NPSR1 2169/4885CYP3A4 377/4885 |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | CFTR, NAT1, ELANE | APEX1 1482/4885NPSR1 1199/4885CYP3A4 956/4885 |
| US-20100158818-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NRDC, NHERF1, MPO | APEX1 285/4885NPSR1 1577/4885CYP3A4 3815/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | APEX1 2504/4885NPSR1 2169/4885CYP3A4 377/4885 |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | FUT6, FUT5, OGT | APEX1 1903/4885NPSR1 927/4885CYP3A4 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.